Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Adoptive immunotherapy (AI) has been applied in the treatment of non-small-cell lung cancer (NSCLC) patients, but the value of postoperative AI has been inconclusive largely as a result of the small number of patients included in each study. We performed a systematic review and meta-analysis to addr...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5019384?pdf=render |
id |
doaj-869c9dd4ecf541629a5dc3ca7563361e |
---|---|
record_format |
Article |
spelling |
doaj-869c9dd4ecf541629a5dc3ca7563361e2020-11-25T02:27:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016263010.1371/journal.pone.0162630Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Yuan ZengWenli RuanJiaxi HeJianrong ZhangWenhua LiangYaoqi ChenQihua HeJianxing HeAdoptive immunotherapy (AI) has been applied in the treatment of non-small-cell lung cancer (NSCLC) patients, but the value of postoperative AI has been inconclusive largely as a result of the small number of patients included in each study. We performed a systematic review and meta-analysis to address this issue for patients with postoperative NSCLC.Pubmed, Embase, Cochrane Library were searched for randomized controlled trials comparing adoptive immunotherapy with control therapies in postoperative NSCLC patients. The primary endpoint was overall survival. Hazard ratio (HR) was estimated and 95% confidence intervals (CI) were calculated using a fixed-effect model.Compared with control therapies, analyses of 4 randomized controlled trials (472 patients) showed a significant benefit of adoptive immunotherapy on survival (hazard ratio [HR] 0.61, 95% CI 0.45-0.84, p = 0.002), and a 39% reduction in the relative risk of death (no evidence of a difference between trials; p = 0.16, I² = 42%). In subgroup analyses by treatment cycles and treatment regimen, significant OS benefit was found in combination therapy of AI with chemotherapy, regardless of whether or not the treatment cycles were more than 10 cycles.Adoptive immunotherapy has the potential to improve overall survival in postoperative NSCLC. The findings suggest this is a valid treatment option for these patients. Further randomized clinical trials are urgently needed.http://europepmc.org/articles/PMC5019384?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuan Zeng Wenli Ruan Jiaxi He Jianrong Zhang Wenhua Liang Yaoqi Chen Qihua He Jianxing He |
spellingShingle |
Yuan Zeng Wenli Ruan Jiaxi He Jianrong Zhang Wenhua Liang Yaoqi Chen Qihua He Jianxing He Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE |
author_facet |
Yuan Zeng Wenli Ruan Jiaxi He Jianrong Zhang Wenhua Liang Yaoqi Chen Qihua He Jianxing He |
author_sort |
Yuan Zeng |
title |
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
title_short |
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
title_full |
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
title_fullStr |
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
title_full_unstemmed |
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
title_sort |
adoptive immunotherapy in postoperative non-small-cell lung cancer: a systematic review and meta-analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Adoptive immunotherapy (AI) has been applied in the treatment of non-small-cell lung cancer (NSCLC) patients, but the value of postoperative AI has been inconclusive largely as a result of the small number of patients included in each study. We performed a systematic review and meta-analysis to address this issue for patients with postoperative NSCLC.Pubmed, Embase, Cochrane Library were searched for randomized controlled trials comparing adoptive immunotherapy with control therapies in postoperative NSCLC patients. The primary endpoint was overall survival. Hazard ratio (HR) was estimated and 95% confidence intervals (CI) were calculated using a fixed-effect model.Compared with control therapies, analyses of 4 randomized controlled trials (472 patients) showed a significant benefit of adoptive immunotherapy on survival (hazard ratio [HR] 0.61, 95% CI 0.45-0.84, p = 0.002), and a 39% reduction in the relative risk of death (no evidence of a difference between trials; p = 0.16, I² = 42%). In subgroup analyses by treatment cycles and treatment regimen, significant OS benefit was found in combination therapy of AI with chemotherapy, regardless of whether or not the treatment cycles were more than 10 cycles.Adoptive immunotherapy has the potential to improve overall survival in postoperative NSCLC. The findings suggest this is a valid treatment option for these patients. Further randomized clinical trials are urgently needed. |
url |
http://europepmc.org/articles/PMC5019384?pdf=render |
work_keys_str_mv |
AT yuanzeng adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT wenliruan adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT jiaxihe adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT jianrongzhang adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT wenhualiang adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT yaoqichen adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT qihuahe adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis AT jianxinghe adoptiveimmunotherapyinpostoperativenonsmallcelllungcancerasystematicreviewandmetaanalysis |
_version_ |
1724841576943845376 |